Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action

Respiration

Volumn 66, Issue 5, 1999, Pages 434-439

  Çelik, Gülfem ^a,b   Kayacan, Oya ^a   Beder, Sumru ^a   Durmaz, Gülten ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Chronic obstructive pulmonary disease; Formoterol; Salmeterol

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; FORMOTEROL FUMARATE; PLACEBO; SALMETEROL; SALMETEROL XINAFOATE;

ADULT; AIRWAY OBSTRUCTION; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEART PALPITATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREMOR;

EID: 0032822578     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000029427     Document Type: Article

References (20)

1. European Respiratory Society (ERS) Consensus statements: Optimal assessments and management of chronic obstructive pulmonary disease. Eur Respir J 1995;8:1398-1420.
2. American Thoracic Society: Definitions, epidemiology, pathophysiology, diagnosis and staging of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S78-S83.
3. Naline E, Zhang Y, Qian Y, Mairon N, Anderson GP, Grandordy B, Advenier C: Relaxant effects and durations of action of formoterol and salmeterol in the isolated human bronchus. Eur Respir J 1994;7:914-920.
4. 2-agonists. Clin Exp Allergy 1992;22:600-605.
5. 2 agonist. BMJ 1990;301:1365-1368.
6. Ullman A, Hedner J, Svedmyr N: Inhaled salmeterol and salbutamol in asthmatic patients: An evaluation of asthma symptoms and the possible development of tachyphylaxis. Am Rev Respir Dis 1990;142:571-575.
7. 1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax 1987;42:487-490.
8. Weir DC, Sherwood BP: Measures of reversibility in response to bronchodilators in chronic airway obstruction: Relation to airway calibre. Thorax 1993;46:43-45.
9. Korry RC, Callahan R, Baren HG, Syner JC: The veterans administration army cooperative study of pulmonary functions 1. Clinical spirometry in normal man. Am J Med 1961;30: 243-258.
10. Hedenström H, Wegener T, Boman G, Wahlandcr B: Effect of inhaled formoterol versus terbutaline on respiratory function in moderate bronchial asthma. Allergy 1992;47:158-163.
11. Faurschou P: Chronic dose-ranging studies with salmeterol. Eur Respir Rev 1991;1:282-287.
12. Schreurs AJM, Sinninghe Damsté HEJ, de Graaff CS, Greefhorst APM: A dose-response study with formoterol turbohaler as maintenance therapy in asthmatic patients. Eur Respir J 1996;9:1678-1683.
13. Van Noord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Macsen FPV: Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action. Eur Respir J 1996;9:1684-1688.
14. Newnham DM, Ingram CG, Earnshaw J, Palmer JBD, Dhillon DP: Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma. Respir Mcd 1993;87: 439-444.
15. Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D'Amato G: Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: A dose-response study. Respir Med 1995;89:357-362.
16. Cazzola M, Santangelo G, Piccolo A, Salzillo A, Matera MG, D'Amato G, Rossi F: Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994;7:103-107.
17. Rabe KF, Jörres R, Nowak D, Behr N. Magnussen H: Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993;147:1436-1441.
18. Vollmer M, Schmidt EW, Ulmer WT: Responder and non-responder in the bronchodilator test? Pneumologie 1995;49:584-589.
19. Vollmer M, Schmidt EW, Ulmer WT: Effect duration and treatment effectiveness of salmeterol, fenoterol and salbutamol in severe forms of respiratory tract obstruction. Pneumologie 1995;49:528-534.
20. Ulrik CS: Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: A single centre randomised, double blind, placebo-controlled, cross-over study. Thorax 1995;50:750-754.